Form 4: Immunocore CEO Reports Equity Transactions and New Grants

Immunocore Holdings plc CEO Bahija Jallal reported the vesting of restricted share units, subsequent sale of shares to cover tax liabilities, and the grant of new equity awards.

Summary

• Bahija Jallal, CEO and Director of Immunocore Holdings plc (IMCR), reported transactions involving the company's ordinary shares and derivative securities.
• On February 17, 2026, 23,817 restricted share units (RSUs) vested, converting into ordinary shares.
• Following the vesting, 11,474 ordinary shares were sold on February 18, 2026, at a weighted average price of $32.35 per share, specifically to satisfy income tax liabilities incurred upon RSU vesting.
• After these transactions, Ms. Jallal beneficially owns 12,343 ordinary shares directly.
• Ms. Jallal was granted 88,573 new restricted share units on February 17, 2026, which will vest in four equal annual installments beginning February 17, 2027.
• Additionally, Ms. Jallal received a grant of 395,066 employee share options on February 17, 2026, with an exercise price of $32.38 per share and an expiration date of February 16, 2036.
• The employee share options will vest 25% on February 17, 2027, with subsequent quarterly installments of 6.25% thereafter.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as slightly positive due to the significant new equity grants (RSUs and options) to the CEO, which reinforce long-term alignment with shareholder interests, despite the routine tax-related share sale.

Positives

• The grant of 88,573 new restricted share units and 395,066 employee share options aligns the CEO's long-term incentives with shareholder value.
• Continued equity awards demonstrate ongoing commitment and confidence in the company's future by management.

Negatives

• The sale of 11,474 ordinary shares, although for tax purposes, reduces the CEO's direct shareholding.

Future Outlook

The CEO's compensation structure includes future vesting events for both restricted share units and employee share options, extending through February 2027 and beyond, subject to continuous service. This indicates a long-term incentive plan for executive retention and performance.

Management Comments

• The shares were sold pursuant to a sell-to-cover arrangement for the purpose of satisfying income tax liabilities incurred upon vesting of restricted share units.

Industry Context

StockSavvy.ai notes that Form 4 filings detailing executive equity transactions, including RSU vesting, tax-related sales, and new grants, are standard disclosures in the biotechnology and pharmaceutical industry. These transactions reflect routine compensation practices designed to align executive interests with long-term company performance.

Stakeholder Impact

• Shareholders gain transparency into the CEO's equity compensation and holdings, which can influence perceptions of management's alignment with shareholder interests.
• The transactions reflect the ongoing compensation structure for key executives, which is a factor in corporate governance and talent retention.

Next Steps

• Future vesting of 88,573 new RSUs in four equal annual installments beginning February 17, 2027.
• Future vesting of 395,066 employee share options, with 25% vesting on February 17, 2027, and 6.25% vesting quarterly thereafter.

Key Dates

Recommendation

This Form 4 details routine insider transactions related to executive compensation, including RSU vesting, a tax-related sell-to-cover, and new equity grants. Such transactions do not typically indicate a change in the company's fundamental outlook or performance, thus a 'hold' recommendation is appropriate as there is no new information to warrant a change in investment thesis.

Keywords

IMCR, Immunocore, Form 4, Insider Transaction, Equity Compensation, Restricted Share Units, Stock Options, CEO, Bahija Jallal